Sarah Holland, Ph.D., is the Chief Business Officer of VectivBio. She has more than 30 years of experience in the pharmaceutical and biotechnology industry. Most recently, Dr. Holland served as Global Head of licensing at Lonza AG where she built the new licensing business unit and led research and development for the company’s Biologics division, encompassing biologics, cell and gene therapy, media and transfection. Prior to Lonza, she was business development and licensing (BD&L) partner for the general medicines and emerging markets (GEM) business unit at Sanofi, where she helped position the company as partner of choice in emerging markets.
Before that, she served at Roche for over a decade in positions of increasing responsibility, culminating as Life Cycle Leader for ALECENSA® (alectinib). She led many deals for Roche Partnering, including licensing ZELBORAF® (vemurafenib) from Plexxikon and a key CNS partnership with PTC Therapeutics. Sarah built and led the team responsible for championing and integrating company acquisitions and drove the Roche strategy for rare diseases. Previously, Dr. Holland held commercial positions in a number of companies culminating as global brand director for FASLODEX® (fulvestrant) at AstraZeneca during global launch.
Dr. Holland served as Board Observer for Affinia Therapeutics and Board Member of BacThera AG and the Swiss Healthcare Licensing Group. She earned an M.A. and D.Phil. in chemistry from the University of Oxford and an MBA from Manchester Business School.